Targeting HER2 Alterations in Non-Small-Cell Lung Cancer: A Comprehensive Review
1Department of Medical Oncology, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Purpose:
HER2 is a critical gene that drives various solid tumors in addition to those of breast cancer. For example, HER2 plays a role in non-small-cell lung cancer (NSCLC). Overexpression, amplification, and point mutations in HER2 have been described in patients with NSCLC; however, the potential roles of these alterations remain unclear.
Methods:
We summarize the evidence regarding the distinct impacts of different HER2 aberrations on antitumor agents. Also, we update the therapeutic efficacy of HER2-targeted agents, including anti-HER2 antibodies, antibody-drug conjugates, and small-molecule tyrosine kinase inhibitors, tested in HER2-aberrant NSCLC.
Results:
Although these drugs are not yet standard treatments, certain patients may benefit from these therapies. In this review, we aim to provide an improved understanding of HER2 aberrations in NSCLC, including NSCLC biology and the impacts of each aberration on prognosis and standard treatment. We also highlight the potential of novel anti-HER2 therapies approved by regulatory bodies and those in clinical development.
Conclusion:
Compared with HER2 amplification or overexpression, HER2 mutations, especially HER2 exon 20 mutations, are emerging as the most clear targetable driver for HER2-directed therapies in lung cancer. De novo and inducible HER2 pathway activation need to be differentially managed. Further investigations with new strategies are needed.
Insights
HER2 mutations, particularly in exon 20, are key targets for lung cancer therapies. Managing HER2 pathway activation requires distinct strategies for better treatment outcomes.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- HER2 (Human Epidermal growth factor Receptor 2) is a significant driver in various solid tumors, including non-small-cell lung cancer (NSCLC).
- Alterations in HER2, such as overexpression, amplification, and mutations, are observed in NSCLC patients, but their precise roles are not fully understood.
Purpose of the Study:
- To review the impact of distinct HER2 aberrations on antitumor agents in NSCLC.
- To update the therapeutic efficacy of HER2-targeted agents in HER2-aberrant NSCLC.
- To enhance understanding of HER2 aberrations, their biological impact, and potential novel therapies.
Main Methods:
- Literature review summarizing evidence on HER2 aberrations and their effects on antitumor agents.
- Analysis of therapeutic efficacy for HER2-targeted agents (antibodies, antibody-drug conjugates, tyrosine kinase inhibitors) in NSCLC.
- Highlighting approved and investigational anti-HER2 therapies.
Main Results:
- Certain HER2-targeted therapies show potential benefit for specific NSCLC patients, though not yet standard treatments.
- HER2 mutations, especially exon 20 mutations, are emerging as the most actionable targets for HER2-directed therapies.
- Differential management strategies are needed for de novo and inducible HER2 pathway activation.
Conclusions:
- HER2 mutations represent a clear target for HER2-directed therapies in lung cancer.
- Further research and novel strategies are essential for optimizing HER2-targeted treatment in NSCLC.
- Understanding the specific roles of HER2 aberrations is crucial for personalized treatment approaches.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...